
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Catalent's Martin De Brauwere and Maria Lopez react to cell therapy innovations and highlight strategies to optimize the drug development and manufacturing process with assistance from a CDMO.
LEARN MORE IN THIS VIDEO:
- Current state of the cellular therapy market and challenges bringing newer therapies to commercialization
- Critical components tied to successful drug development and manufacturing of cell therapies
- Remaining current with regulatory guidance tied to cell therapies
- Proper oversight of supply chains tied to a cell therapy project






